Barrington analyst Michael Petusky lowered the firm’s price target on Anika Therapeutics (ANIK) to $15 from $19 and keeps an Outperform rating on the shares, citing “incrementally negative Hyalofast news” for the firm’s lowered target. However, shares are “meaningfully undervalued and trading near max skepticism after yesterday’s 27% decline,” the analyst argues.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK: